| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 37 | 2025 | 976 | 5.020 |
Why?
|
| Antihypertensive Agents | 27 | 2025 | 352 | 3.960 |
Why?
|
| Blood Pressure | 32 | 2026 | 862 | 2.860 |
Why?
|
| Blood Pressure Determination | 9 | 2020 | 102 | 1.770 |
Why?
|
| Cardiovascular Diseases | 17 | 2025 | 1140 | 1.710 |
Why?
|
| Dementia | 12 | 2025 | 245 | 1.700 |
Why?
|
| Aged | 61 | 2025 | 10544 | 1.490 |
Why?
|
| Humans | 119 | 2026 | 32814 | 1.460 |
Why?
|
| Frail Elderly | 4 | 2025 | 71 | 1.270 |
Why?
|
| Electronic Health Records | 7 | 2025 | 182 | 1.260 |
Why?
|
| Female | 86 | 2026 | 20271 | 1.220 |
Why?
|
| Male | 79 | 2026 | 19650 | 1.140 |
Why?
|
| Obesity | 15 | 2026 | 1152 | 1.030 |
Why?
|
| Medicare | 5 | 2025 | 213 | 1.000 |
Why?
|
| Renal Insufficiency, Chronic | 8 | 2025 | 297 | 0.990 |
Why?
|
| Subacute Care | 1 | 2025 | 15 | 0.930 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2024 | 146 | 0.910 |
Why?
|
| Anemia, Sickle Cell | 6 | 2010 | 47 | 0.890 |
Why?
|
| Health Status | 6 | 2017 | 402 | 0.880 |
Why?
|
| Middle Aged | 49 | 2026 | 12133 | 0.880 |
Why?
|
| Patient Readmission | 1 | 2025 | 134 | 0.850 |
Why?
|
| Psychotic Disorders | 1 | 2024 | 11 | 0.840 |
Why?
|
| Aged, 80 and over | 21 | 2025 | 4034 | 0.840 |
Why?
|
| Patient Discharge | 1 | 2025 | 204 | 0.830 |
Why?
|
| Anthrax Vaccines | 3 | 2013 | 4 | 0.820 |
Why?
|
| Antibody Formation | 4 | 2013 | 47 | 0.810 |
Why?
|
| Nursing Homes | 1 | 2023 | 42 | 0.780 |
Why?
|
| United States | 24 | 2025 | 4109 | 0.770 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2026 | 532 | 0.750 |
Why?
|
| Genome-Wide Association Study | 11 | 2015 | 549 | 0.750 |
Why?
|
| Severity of Illness Index | 6 | 2025 | 881 | 0.740 |
Why?
|
| Diabetes Mellitus, Type 2 | 10 | 2023 | 1462 | 0.730 |
Why?
|
| Myocardial Infarction | 5 | 2023 | 483 | 0.660 |
Why?
|
| Polymorphism, Single Nucleotide | 16 | 2017 | 1066 | 0.650 |
Why?
|
| Life Style | 7 | 2023 | 407 | 0.640 |
Why?
|
| Risk Factors | 20 | 2024 | 3976 | 0.630 |
Why?
|
| Ethnic Groups | 7 | 2017 | 474 | 0.610 |
Why?
|
| Mobility Limitation | 2 | 2017 | 220 | 0.590 |
Why?
|
| Adult | 29 | 2026 | 9569 | 0.560 |
Why?
|
| Wet Macular Degeneration | 1 | 2017 | 3 | 0.550 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 175 | 0.540 |
Why?
|
| Quality of Life | 5 | 2010 | 962 | 0.530 |
Why?
|
| Visual Acuity | 1 | 2017 | 77 | 0.520 |
Why?
|
| Acoustic Stimulation | 2 | 2015 | 125 | 0.470 |
Why?
|
| Dental Health Services | 2 | 2012 | 11 | 0.450 |
Why?
|
| Accidental Falls | 3 | 2025 | 221 | 0.450 |
Why?
|
| Emergency Service, Hospital | 4 | 2020 | 490 | 0.450 |
Why?
|
| Health Services Accessibility | 4 | 2010 | 252 | 0.450 |
Why?
|
| Hot Flashes | 1 | 2015 | 46 | 0.450 |
Why?
|
| Electric Stimulation | 1 | 2015 | 106 | 0.450 |
Why?
|
| Neural Pathways | 1 | 2015 | 95 | 0.440 |
Why?
|
| Cohort Studies | 11 | 2024 | 1844 | 0.430 |
Why?
|
| Models, Genetic | 3 | 2012 | 94 | 0.420 |
Why?
|
| Age Factors | 9 | 2025 | 1197 | 0.420 |
Why?
|
| Overweight | 5 | 2026 | 263 | 0.410 |
Why?
|
| Glomerular Filtration Rate | 6 | 2021 | 309 | 0.400 |
Why?
|
| Fluorides, Topical | 2 | 2010 | 6 | 0.390 |
Why?
|
| Stomatognathic Diseases | 1 | 2012 | 5 | 0.380 |
Why?
|
| Genes, MHC Class II | 1 | 2012 | 4 | 0.380 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 4 | 2020 | 29 | 0.370 |
Why?
|
| Uncertainty | 1 | 2012 | 11 | 0.370 |
Why?
|
| Myocardial Contraction | 2 | 2009 | 59 | 0.370 |
Why?
|
| Retrospective Studies | 9 | 2025 | 3705 | 0.370 |
Why?
|
| Body Mass Index | 10 | 2026 | 908 | 0.350 |
Why?
|
| HLA-DQ Antigens | 1 | 2011 | 8 | 0.350 |
Why?
|
| HLA-DR Antigens | 1 | 2011 | 8 | 0.350 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 97 | 0.350 |
Why?
|
| Longitudinal Studies | 7 | 2025 | 779 | 0.340 |
Why?
|
| Child, Preschool | 13 | 2013 | 1282 | 0.330 |
Why?
|
| Proxy | 1 | 2010 | 8 | 0.330 |
Why?
|
| Bayes Theorem | 2 | 2011 | 85 | 0.320 |
Why?
|
| Cognition | 5 | 2023 | 551 | 0.320 |
Why?
|
| Parents | 2 | 2010 | 148 | 0.320 |
Why?
|
| Silene | 1 | 2009 | 1 | 0.320 |
Why?
|
| Flowers | 1 | 2009 | 2 | 0.320 |
Why?
|
| Selection, Genetic | 1 | 2009 | 9 | 0.310 |
Why?
|
| Child | 16 | 2013 | 2478 | 0.310 |
Why?
|
| Mental Health | 1 | 2010 | 128 | 0.310 |
Why?
|
| Anti-Obesity Agents | 2 | 2026 | 9 | 0.300 |
Why?
|
| Phentermine | 2 | 2026 | 9 | 0.300 |
Why?
|
| Geriatric Assessment | 2 | 2025 | 388 | 0.300 |
Why?
|
| Follow-Up Studies | 11 | 2025 | 2285 | 0.300 |
Why?
|
| Prevalence | 4 | 2022 | 1002 | 0.290 |
Why?
|
| Psychometrics | 1 | 2009 | 137 | 0.290 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 413 | 0.280 |
Why?
|
| Adolescent | 18 | 2015 | 3640 | 0.280 |
Why?
|
| Behavior Therapy | 2 | 2020 | 103 | 0.280 |
Why?
|
| Risk Assessment | 4 | 2024 | 1461 | 0.280 |
Why?
|
| Residence Characteristics | 1 | 2010 | 197 | 0.280 |
Why?
|
| Ventricular Function, Left | 1 | 2009 | 252 | 0.270 |
Why?
|
| Acute Coronary Syndrome | 2 | 2023 | 203 | 0.270 |
Why?
|
| Wisconsin | 7 | 2012 | 19 | 0.270 |
Why?
|
| African Americans | 8 | 2019 | 1424 | 0.270 |
Why?
|
| Stroke | 2 | 2023 | 609 | 0.270 |
Why?
|
| Weight Loss | 5 | 2026 | 457 | 0.260 |
Why?
|
| Medicaid | 4 | 2011 | 99 | 0.250 |
Why?
|
| Creatinine | 3 | 2022 | 198 | 0.240 |
Why?
|
| Haplotypes | 5 | 2015 | 220 | 0.240 |
Why?
|
| Treatment Outcome | 8 | 2025 | 3441 | 0.240 |
Why?
|
| Neoplasms | 2 | 2025 | 762 | 0.240 |
Why?
|
| Systole | 3 | 2020 | 98 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2025 | 1307 | 0.240 |
Why?
|
| Skilled Nursing Facilities | 1 | 2025 | 12 | 0.230 |
Why?
|
| Kidney Diseases | 2 | 2019 | 250 | 0.230 |
Why?
|
| Home Care Services | 1 | 2025 | 53 | 0.220 |
Why?
|
| Proportional Hazards Models | 7 | 2025 | 764 | 0.220 |
Why?
|
| Cross-Sectional Studies | 7 | 2020 | 1572 | 0.220 |
Why?
|
| Alleles | 4 | 2015 | 253 | 0.220 |
Why?
|
| Brain | 4 | 2021 | 946 | 0.220 |
Why?
|
| HIV-1 | 3 | 2015 | 45 | 0.220 |
Why?
|
| Incidence | 4 | 2022 | 1239 | 0.210 |
Why?
|
| England | 1 | 2024 | 4 | 0.210 |
Why?
|
| State Medicine | 1 | 2024 | 3 | 0.210 |
Why?
|
| Hispanic Americans | 6 | 2013 | 930 | 0.210 |
Why?
|
| Algorithms | 3 | 2024 | 511 | 0.210 |
Why?
|
| Critical Illness | 1 | 2024 | 84 | 0.210 |
Why?
|
| HIV Infections | 3 | 2015 | 424 | 0.210 |
Why?
|
| Primary Prevention | 1 | 2024 | 56 | 0.200 |
Why?
|
| Heart Failure | 2 | 2023 | 695 | 0.200 |
Why?
|
| Apolipoproteins | 2 | 2016 | 200 | 0.200 |
Why?
|
| Hospitalization | 3 | 2023 | 488 | 0.200 |
Why?
|
| Lipoproteins, HDL | 2 | 2016 | 252 | 0.200 |
Why?
|
| Regression Analysis | 2 | 2016 | 288 | 0.190 |
Why?
|
| Cerebrovascular Circulation | 3 | 2022 | 95 | 0.190 |
Why?
|
| Health Status Indicators | 2 | 2016 | 74 | 0.190 |
Why?
|
| Breast Neoplasms | 2 | 2025 | 754 | 0.180 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2022 | 22 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2015 | 835 | 0.180 |
Why?
|
| Homebound Persons | 1 | 2021 | 9 | 0.180 |
Why?
|
| Dental Care | 3 | 2011 | 18 | 0.180 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2022 | 65 | 0.180 |
Why?
|
| Survival Analysis | 2 | 2019 | 486 | 0.170 |
Why?
|
| Carotid Artery Diseases | 2 | 2014 | 116 | 0.170 |
Why?
|
| Health Surveys | 2 | 2019 | 200 | 0.170 |
Why?
|
| Immunoglobulin G | 2 | 2012 | 128 | 0.170 |
Why?
|
| Sample Size | 2 | 2012 | 39 | 0.170 |
Why?
|
| Sex Factors | 3 | 2019 | 676 | 0.170 |
Why?
|
| Body Height | 2 | 2011 | 33 | 0.170 |
Why?
|
| Diet Therapy | 1 | 2020 | 15 | 0.170 |
Why?
|
| European Continental Ancestry Group | 7 | 2014 | 1163 | 0.170 |
Why?
|
| Bicarbonates | 1 | 2020 | 11 | 0.170 |
Why?
|
| Cystatin C | 1 | 2020 | 32 | 0.160 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 302 | 0.160 |
Why?
|
| Genetic Variation | 4 | 2019 | 246 | 0.160 |
Why?
|
| Advance Care Planning | 1 | 2019 | 15 | 0.160 |
Why?
|
| Health Care Costs | 1 | 2020 | 122 | 0.150 |
Why?
|
| Documentation | 1 | 2019 | 47 | 0.150 |
Why?
|
| Genotype | 4 | 2015 | 731 | 0.140 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 258 | 0.140 |
Why?
|
| Data Collection | 1 | 2018 | 185 | 0.140 |
Why?
|
| Infant | 6 | 2013 | 1083 | 0.140 |
Why?
|
| Exercise Therapy | 1 | 2020 | 271 | 0.140 |
Why?
|
| Dental Care for Children | 2 | 2009 | 4 | 0.140 |
Why?
|
| Diet | 3 | 2020 | 390 | 0.140 |
Why?
|
| Patient-Centered Care | 1 | 2018 | 72 | 0.140 |
Why?
|
| Retirement | 1 | 2017 | 13 | 0.140 |
Why?
|
| Syncope | 1 | 2018 | 27 | 0.140 |
Why?
|
| Decision Making | 1 | 2019 | 202 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 39 | 0.130 |
Why?
|
| Menopause | 2 | 2015 | 97 | 0.130 |
Why?
|
| Vasodilation | 2 | 2016 | 92 | 0.130 |
Why?
|
| Linkage Disequilibrium | 2 | 2015 | 185 | 0.130 |
Why?
|
| Mass Screening | 1 | 2019 | 268 | 0.130 |
Why?
|
| Lipoproteins | 1 | 2017 | 86 | 0.130 |
Why?
|
| Computer Simulation | 2 | 2025 | 223 | 0.120 |
Why?
|
| Tilt-Table Test | 1 | 2015 | 13 | 0.120 |
Why?
|
| Postural Orthostatic Tachycardia Syndrome | 1 | 2015 | 9 | 0.120 |
Why?
|
| Allostasis | 1 | 2015 | 12 | 0.120 |
Why?
|
| Vasoconstriction | 1 | 2016 | 43 | 0.120 |
Why?
|
| Temporal Lobe | 1 | 2015 | 30 | 0.120 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2015 | 2 | 0.120 |
Why?
|
| Healthcare Disparities | 2 | 2018 | 178 | 0.120 |
Why?
|
| Postural Balance | 1 | 2017 | 180 | 0.120 |
Why?
|
| Genetics, Population | 2 | 2012 | 31 | 0.120 |
Why?
|
| Claudins | 1 | 2015 | 8 | 0.110 |
Why?
|
| Gene Regulatory Networks | 2 | 2012 | 44 | 0.110 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2015 | 18 | 0.110 |
Why?
|
| Interleukins | 1 | 2015 | 18 | 0.110 |
Why?
|
| Oxygen | 1 | 2016 | 144 | 0.110 |
Why?
|
| Anthrax | 2 | 2013 | 5 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2015 | 40 | 0.110 |
Why?
|
| Disease Susceptibility | 1 | 2015 | 58 | 0.110 |
Why?
|
| Mitochondrial Proteins | 1 | 2015 | 71 | 0.110 |
Why?
|
| DNA Copy Number Variations | 2 | 2011 | 11 | 0.110 |
Why?
|
| Young Adult | 8 | 2015 | 2734 | 0.110 |
Why?
|
| Body Weight | 2 | 2020 | 301 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 384 | 0.110 |
Why?
|
| Prediabetic State | 1 | 2015 | 72 | 0.110 |
Why?
|
| Adiponectin | 1 | 2015 | 103 | 0.110 |
Why?
|
| Major Histocompatibility Complex | 1 | 2014 | 16 | 0.110 |
Why?
|
| Vitamin D | 1 | 2015 | 189 | 0.110 |
Why?
|
| Information Storage and Retrieval | 1 | 2014 | 25 | 0.110 |
Why?
|
| Physical Fitness | 1 | 2015 | 133 | 0.110 |
Why?
|
| Physicians' Offices | 2 | 2011 | 10 | 0.110 |
Why?
|
| Social Class | 3 | 2009 | 93 | 0.110 |
Why?
|
| Phenotype | 3 | 2011 | 638 | 0.100 |
Why?
|
| Reproducibility of Results | 3 | 2015 | 767 | 0.100 |
Why?
|
| Radiosurgery | 1 | 2017 | 362 | 0.100 |
Why?
|
| Models, Statistical | 2 | 2012 | 180 | 0.100 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2014 | 12 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 208 | 0.100 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2014 | 35 | 0.100 |
Why?
|
| Diabetic Retinopathy | 1 | 2014 | 73 | 0.100 |
Why?
|
| Heart Rate | 1 | 2015 | 343 | 0.100 |
Why?
|
| Indoles | 1 | 2014 | 56 | 0.100 |
Why?
|
| Dentists | 2 | 2011 | 2 | 0.100 |
Why?
|
| Diabetic Angiopathies | 1 | 2014 | 145 | 0.100 |
Why?
|
| Appendicitis | 1 | 2013 | 15 | 0.100 |
Why?
|
| Appendectomy | 1 | 2013 | 19 | 0.100 |
Why?
|
| Medically Underserved Area | 2 | 2011 | 23 | 0.100 |
Why?
|
| Bacillus anthracis | 1 | 2013 | 9 | 0.100 |
Why?
|
| Immunity, Cellular | 1 | 2013 | 20 | 0.100 |
Why?
|
| Hospitals, Pediatric | 1 | 2013 | 47 | 0.100 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2014 | 138 | 0.100 |
Why?
|
| Adiposity | 3 | 2025 | 198 | 0.100 |
Why?
|
| Disease Progression | 2 | 2025 | 594 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 2 | 2026 | 111 | 0.100 |
Why?
|
| Estrogens | 1 | 2014 | 169 | 0.100 |
Why?
|
| Diabetic Nephropathies | 1 | 2014 | 227 | 0.100 |
Why?
|
| Calcifediol | 1 | 2012 | 8 | 0.100 |
Why?
|
| Bipolar Disorder | 1 | 2012 | 15 | 0.100 |
Why?
|
| Pregnancy | 1 | 2015 | 981 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2012 | 28 | 0.090 |
Why?
|
| Risk | 3 | 2020 | 315 | 0.090 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2012 | 3 | 0.090 |
Why?
|
| Cadherins | 1 | 2012 | 27 | 0.090 |
Why?
|
| Epistasis, Genetic | 1 | 2012 | 44 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 576 | 0.090 |
Why?
|
| Students, Medical | 1 | 2014 | 132 | 0.090 |
Why?
|
| Curriculum | 1 | 2014 | 211 | 0.090 |
Why?
|
| Animals | 7 | 2015 | 7570 | 0.090 |
Why?
|
| Antibodies, Bacterial | 1 | 2012 | 31 | 0.090 |
Why?
|
| Health Policy | 2 | 2010 | 93 | 0.090 |
Why?
|
| Depression | 1 | 2015 | 448 | 0.090 |
Why?
|
| Receptors, Interleukin | 1 | 2011 | 16 | 0.090 |
Why?
|
| Cholesterol, HDL | 1 | 2012 | 175 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 69 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 647 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2011 | 49 | 0.090 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2011 | 47 | 0.090 |
Why?
|
| Atherosclerosis | 1 | 2017 | 788 | 0.080 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2011 | 59 | 0.080 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2011 | 148 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2011 | 220 | 0.080 |
Why?
|
| Smallpox Vaccine | 1 | 2010 | 2 | 0.080 |
Why?
|
| Longevity | 1 | 2010 | 21 | 0.080 |
Why?
|
| Genome, Human | 1 | 2011 | 132 | 0.080 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2010 | 18 | 0.080 |
Why?
|
| Counseling | 2 | 2020 | 98 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2016 | 2329 | 0.080 |
Why?
|
| Ultrasonography | 2 | 2009 | 381 | 0.080 |
Why?
|
| Fee-for-Service Plans | 1 | 2010 | 12 | 0.080 |
Why?
|
| Calcium | 1 | 2012 | 323 | 0.080 |
Why?
|
| Birds | 1 | 2009 | 4 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2011 | 265 | 0.080 |
Why?
|
| Female Athlete Triad Syndrome | 1 | 2009 | 1 | 0.080 |
Why?
|
| Managed Care Programs | 1 | 2010 | 41 | 0.080 |
Why?
|
| Research Design | 1 | 2012 | 332 | 0.080 |
Why?
|
| Cause of Death | 3 | 2016 | 240 | 0.080 |
Why?
|
| Indians, North American | 1 | 2010 | 110 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2026 | 525 | 0.080 |
Why?
|
| Cariostatic Agents | 1 | 2009 | 4 | 0.080 |
Why?
|
| Vascular Diseases | 1 | 2010 | 68 | 0.080 |
Why?
|
| Urban Population | 1 | 2010 | 93 | 0.080 |
Why?
|
| Athletes | 1 | 2009 | 73 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2010 | 171 | 0.070 |
Why?
|
| Hypopharynx | 1 | 2008 | 2 | 0.070 |
Why?
|
| Language | 1 | 2009 | 45 | 0.070 |
Why?
|
| Mucins | 1 | 2008 | 17 | 0.070 |
Why?
|
| Larynx | 1 | 2008 | 19 | 0.070 |
Why?
|
| Gastroesophageal Reflux | 1 | 2008 | 20 | 0.070 |
Why?
|
| Orthodontics, Corrective | 1 | 2008 | 1 | 0.070 |
Why?
|
| Office Visits | 1 | 2008 | 73 | 0.070 |
Why?
|
| Case-Control Studies | 4 | 2012 | 877 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2011 | 469 | 0.070 |
Why?
|
| Pain Measurement | 2 | 2025 | 356 | 0.070 |
Why?
|
| Bone Density | 1 | 2009 | 203 | 0.070 |
Why?
|
| Health Personnel | 1 | 2009 | 130 | 0.070 |
Why?
|
| Amenorrhea | 1 | 2007 | 4 | 0.070 |
Why?
|
| Rural Population | 1 | 2010 | 286 | 0.070 |
Why?
|
| Running | 1 | 2007 | 19 | 0.070 |
Why?
|
| Pain | 1 | 2010 | 295 | 0.070 |
Why?
|
| Tissue Survival | 1 | 2007 | 13 | 0.070 |
Why?
|
| Organ Size | 2 | 2019 | 219 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2007 | 69 | 0.070 |
Why?
|
| Orthodontics | 1 | 2007 | 1 | 0.060 |
Why?
|
| Malocclusion | 1 | 2007 | 5 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 888 | 0.060 |
Why?
|
| Oxygenases | 1 | 2006 | 3 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 949 | 0.060 |
Why?
|
| Age Distribution | 3 | 2016 | 201 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 155 | 0.060 |
Why?
|
| Echocardiography | 1 | 2007 | 182 | 0.060 |
Why?
|
| Basal Metabolism | 1 | 2026 | 9 | 0.060 |
Why?
|
| Kidney Function Tests | 2 | 2016 | 107 | 0.060 |
Why?
|
| Myocardium | 1 | 2007 | 191 | 0.060 |
Why?
|
| Thrombospondin 1 | 1 | 2005 | 7 | 0.060 |
Why?
|
| Erythrocytes | 1 | 2005 | 48 | 0.060 |
Why?
|
| Genetic Association Studies | 2 | 2015 | 148 | 0.060 |
Why?
|
| Health Expenditures | 2 | 2020 | 68 | 0.060 |
Why?
|
| SEER Program | 1 | 2025 | 33 | 0.060 |
Why?
|
| Comparative Effectiveness Research | 1 | 2025 | 29 | 0.060 |
Why?
|
| California | 1 | 2025 | 66 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2025 | 114 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2025 | 205 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2024 | 115 | 0.050 |
Why?
|
| Electronics | 1 | 2023 | 14 | 0.050 |
Why?
|
| Genetic Loci | 2 | 2015 | 146 | 0.050 |
Why?
|
| Exercise | 2 | 2020 | 679 | 0.050 |
Why?
|
| Internationality | 1 | 2023 | 23 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2025 | 222 | 0.050 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2023 | 31 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2025 | 252 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2023 | 162 | 0.050 |
Why?
|
| Motor Activity | 2 | 2015 | 327 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2023 | 307 | 0.050 |
Why?
|
| Lipids | 1 | 2023 | 229 | 0.050 |
Why?
|
| Waist Circumference | 2 | 2012 | 92 | 0.050 |
Why?
|
| Kidney Tubules | 1 | 2021 | 26 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 136 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2025 | 429 | 0.040 |
Why?
|
| Program Evaluation | 2 | 2014 | 181 | 0.040 |
Why?
|
| Independent Living | 1 | 2021 | 105 | 0.040 |
Why?
|
| Medicare Part A | 1 | 2020 | 5 | 0.040 |
Why?
|
| Medicare Part B | 1 | 2020 | 5 | 0.040 |
Why?
|
| Medicare Part D | 1 | 2020 | 10 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2020 | 18 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 65 | 0.040 |
Why?
|
| Health Services | 1 | 2020 | 39 | 0.040 |
Why?
|
| Nutrition Surveys | 2 | 2011 | 150 | 0.040 |
Why?
|
| North Carolina | 1 | 2024 | 1546 | 0.040 |
Why?
|
| Time Factors | 2 | 2016 | 2183 | 0.040 |
Why?
|
| Terminal Care | 1 | 2019 | 25 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2020 | 238 | 0.040 |
Why?
|
| Albuminuria | 1 | 2020 | 180 | 0.040 |
Why?
|
| Sex Distribution | 2 | 2010 | 185 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 436 | 0.040 |
Why?
|
| Patient Participation | 1 | 2019 | 87 | 0.040 |
Why?
|
| Gender Identity | 1 | 2018 | 28 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2019 | 58 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2019 | 410 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 894 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2018 | 92 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2018 | 125 | 0.030 |
Why?
|
| Nomograms | 1 | 2017 | 35 | 0.030 |
Why?
|
| Death | 1 | 2017 | 53 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 188 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 95 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 289 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2016 | 24 | 0.030 |
Why?
|
| Logistic Models | 2 | 2009 | 783 | 0.030 |
Why?
|
| Animal Feed | 1 | 2015 | 17 | 0.030 |
Why?
|
| Exercise Test | 1 | 2017 | 223 | 0.030 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2015 | 10 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 412 | 0.030 |
Why?
|
| Rest | 1 | 2016 | 52 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 240 | 0.030 |
Why?
|
| Posture | 1 | 2015 | 56 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2017 | 160 | 0.030 |
Why?
|
| Baroreflex | 1 | 2015 | 85 | 0.030 |
Why?
|
| Rats | 2 | 2010 | 1606 | 0.030 |
Why?
|
| Models, Neurological | 1 | 2016 | 119 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 265 | 0.030 |
Why?
|
| Diet, Reducing | 1 | 2015 | 100 | 0.030 |
Why?
|
| Weight Gain | 1 | 2015 | 112 | 0.030 |
Why?
|
| Computational Biology | 1 | 2015 | 94 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 282 | 0.030 |
Why?
|
| Librarians | 1 | 2014 | 3 | 0.030 |
Why?
|
| Africa | 1 | 2014 | 28 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2015 | 187 | 0.030 |
Why?
|
| Models, Biological | 1 | 2016 | 392 | 0.030 |
Why?
|
| Basilar Artery | 1 | 2014 | 9 | 0.030 |
Why?
|
| Viral Load | 1 | 2014 | 73 | 0.030 |
Why?
|
| Problem-Based Learning | 1 | 2014 | 28 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 565 | 0.030 |
Why?
|
| Diet, Atherogenic | 1 | 2014 | 61 | 0.030 |
Why?
|
| Haplorhini | 1 | 2014 | 69 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 563 | 0.030 |
Why?
|
| Carotid Artery, Internal | 1 | 2014 | 32 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 99 | 0.030 |
Why?
|
| African Continental Ancestry Group | 1 | 2015 | 363 | 0.030 |
Why?
|
| HLA-A Antigens | 1 | 2013 | 2 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 2013 | 26 | 0.020 |
Why?
|
| Homozygote | 1 | 2013 | 58 | 0.020 |
Why?
|
| Random Allocation | 1 | 2014 | 229 | 0.020 |
Why?
|
| Heterozygote | 1 | 2013 | 61 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2013 | 59 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 369 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 89 | 0.020 |
Why?
|
| Acute Disease | 1 | 2013 | 259 | 0.020 |
Why?
|
| Obesity, Abdominal | 1 | 2012 | 24 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 183 | 0.020 |
Why?
|
| OX40 Ligand | 1 | 2011 | 6 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2011 | 9 | 0.020 |
Why?
|
| Vitamins | 1 | 2012 | 73 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2012 | 63 | 0.020 |
Why?
|
| Models, Animal | 1 | 2012 | 171 | 0.020 |
Why?
|
| Vaccination | 1 | 2013 | 146 | 0.020 |
Why?
|
| Colitis, Ulcerative | 1 | 2011 | 24 | 0.020 |
Why?
|
| Alberta | 1 | 2011 | 1 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 40 | 0.020 |
Why?
|
| Crohn Disease | 1 | 2011 | 29 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 622 | 0.020 |
Why?
|
| Tooth Diseases | 1 | 2011 | 6 | 0.020 |
Why?
|
| Self Concept | 1 | 2011 | 44 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 445 | 0.020 |
Why?
|
| Urban Health | 1 | 2011 | 15 | 0.020 |
Why?
|
| Periodontal Diseases | 1 | 2011 | 18 | 0.020 |
Why?
|
| Fasting | 1 | 2011 | 94 | 0.020 |
Why?
|
| Rural Health | 1 | 2011 | 44 | 0.020 |
Why?
|
| Mouth Diseases | 1 | 2011 | 21 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2013 | 694 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 603 | 0.020 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2010 | 1 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2010 | 5 | 0.020 |
Why?
|
| Triglycerides | 1 | 2011 | 228 | 0.020 |
Why?
|
| Genes | 1 | 2010 | 15 | 0.020 |
Why?
|
| Markov Chains | 1 | 2010 | 32 | 0.020 |
Why?
|
| Poverty | 1 | 2011 | 116 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 1545 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2010 | 29 | 0.020 |
Why?
|
| Midwestern United States | 1 | 2009 | 8 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 573 | 0.020 |
Why?
|
| Energy Intake | 1 | 2009 | 128 | 0.020 |
Why?
|
| Communication Barriers | 1 | 2009 | 23 | 0.020 |
Why?
|
| Pepsin A | 1 | 2008 | 4 | 0.020 |
Why?
|
| Epithelium | 1 | 2008 | 22 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2008 | 69 | 0.020 |
Why?
|
| Income | 1 | 2009 | 67 | 0.020 |
Why?
|
| Minority Groups | 1 | 2009 | 86 | 0.020 |
Why?
|
| Marital Status | 1 | 2008 | 23 | 0.020 |
Why?
|
| Educational Status | 1 | 2009 | 183 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 360 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2008 | 134 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 255 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2007 | 20 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2007 | 85 | 0.020 |
Why?
|
| Continental Population Groups | 1 | 2008 | 236 | 0.020 |
Why?
|
| Gene Expression | 1 | 2008 | 334 | 0.020 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2007 | 18 | 0.020 |
Why?
|
| Dental Health Surveys | 1 | 2007 | 1 | 0.020 |
Why?
|
| Insurance, Dental | 1 | 2007 | 2 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2007 | 89 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2008 | 498 | 0.020 |
Why?
|
| Oral Health | 1 | 2007 | 29 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2007 | 272 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2007 | 158 | 0.020 |
Why?
|
| Kinetics | 1 | 2006 | 206 | 0.020 |
Why?
|
| Nystatin | 1 | 2005 | 2 | 0.010 |
Why?
|
| Erythrocyte Membrane | 1 | 2005 | 2 | 0.010 |
Why?
|
| Osmosis | 1 | 2005 | 4 | 0.010 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2005 | 4 | 0.010 |
Why?
|
| Dehydration | 1 | 2005 | 9 | 0.010 |
Why?
|
| Sucrose | 1 | 2005 | 18 | 0.010 |
Why?
|
| Capillaries | 1 | 2005 | 23 | 0.010 |
Why?
|
| Phosphatidylserines | 1 | 2005 | 8 | 0.010 |
Why?
|
| Women's Health | 1 | 2007 | 235 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2005 | 103 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2005 | 186 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 754 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 820 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 1012 | 0.010 |
Why?
|
| Kidney | 1 | 2005 | 520 | 0.010 |
Why?
|
| Mice | 1 | 2005 | 2512 | 0.010 |
Why?
|